Dr. Grigoriadis' clinical research program focuses on the treatment of Mood Disorders in women across the reproductive life stages. This research program spans from the mechanistic to the societal level and has three main research foci: novel interventions, mechanisms of antidepressant response and factors affecting outcome. The novel interventions stream includes pharmacological as well as psychotherapeutic modalities. The second research stream, mechanisms of antidepressant response, has its origins in her fascination in the interplay between neuroendocrinology and clinical psychiatry in the development and presentation of mood disorders. The focus of this stream is the examination of the etiologic and therapeutic implications of the gender differences seen in depression, specifically in women at different life stages. The third research stream focuses on factors affecting treatment response and is broad in scope from an examination of other psychiatric symptoms to cultural practices and issues surrounding treatment decisions made by patients as well as their health care providers. All three streams utilize her training as a researcher and clinician to not only better understand mood disorders women experience but also to determine and promote evidence based treatment options.
Dr. Grigoriadis is the Head of the Women’s Mood and Anxiety Clinic: Reproductive Transitions at Sunnybrook Health Sciences Centre and scientist at the Sunnybrook Research Institute. She continues to hold an appointment at the University Health Network and was the Academic Leader of the Reproductive Life Stages Program at Women’s College Hospital.
Dr. Grigoriadis completed her medical degree at McMaster University and her psychiatry residency at the University of Toronto. Prior to Medical school, she completed a MA and PhD in Psychology (Clinical Program) at Queen’s University, and internship in Clinical Psychology at the Toronto Hospital. Dr. Grigoriadis’ clinical interests include women with depression especially during pregnancy, the postpartum period and during perimenopause. Her treatment strategies include both the use of pharmacotherapy as well as short-term psychotherapies.